STAT5 inhibitors have been used to abrogate the constitutive activation of STAT5 signaling in cancer, and tyrosine kinase inhibitors (TKIs) that target the upstream signaling molecules of STAT5 — such as JAK, FLT3, and BCR-ABL — have been shown to be effective in clinical settings (46). Here, BCR is linked to cancer.